BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Feb. 10, 2026

Feb. 10, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biogen, Eisai, Hemex, Krystal, Median Technologies, Peijia, Sanofi.
Read More

Regulatory actions for Feb. 10, 2026

Feb. 10, 2026
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Akeso, Astrazeneca, Daiichi Sankyo, Everest Medicines, Kelun-Biotech, Neurophet.
Read More

Regulatory actions for Feb. 9, 2026

Feb. 9, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Akeso, Everest, GSK, Kelun-Biotech, Kite, Neurophet, P+F Products and Features, Partner Therapeutics, Pfizer, Spinal Resources, Zimmer Biomet.
Read More

Regulatory actions for Feb. 6, 2026

Feb. 6, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biocomposites, Eyas, Insightec, Mirum, Sonorous Neurovascular.
Read More

Regulatory actions for Feb. 5, 2026

Feb. 5, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Acarix, Balt, Cumberland, Hologic, Ingeneron, Oncolytics, TSC.
Read More

Regulatory actions for Feb. 4, 2026

Feb. 4, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Acadia, Astrazeneca, Daiichi Sankyo, Medtronic, Promega, Quanterix, Relay, Revealdx, Zeiss.
Read More

Regulatory actions for Feb. 3, 2026

Feb. 3, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aquestive, ARS, Astrazeneca, Cynosure Lutronic, Elevar, Exelixis, Galderma, GE, Incyte, Moonlake, Natera, OS Therapies, Pharming, Tuhura.
Read More

Regulatory actions for Feb. 3, 2026

Feb. 3, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations in Asia-Pacific: Almirall, Bioarctic, Biogen, Drug Farm, Eisai, Huahui, Otsuka, Quoin.
Read More

Regulatory actions for Feb. 2, 2026

Feb. 2, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Chiesi, Eli Lilly, Johnson & Johnson, Protalix, Sanofi, Ultragenyx, Unicycive.
Read More

Regulatory actions for Jan. 30, 2026

Jan. 30, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Almirall, Elevar, Summit, Tenpoint.
Read More
Previous 1 2 … 6 7 8 9 10 11 12 13 14 … 339 340 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing